Browse our 650+ Publications​

Latest Publications

Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo

Kooreman et al.
Cell Stem Cell
Papers
April 2018
Authors and Affiliates
Nigel G. Kooreman,1,2,3,4,13 Youngkyun Kim,1,2,3,7 Patricia E. de Almeida,1,2,3 Vittavat Termglinchan,1,2,3 Sebastian Diecke,8,9,10 Ning-Yi Shao,1,2,3 Tzu-Tang Wei,1,2,3 Hyoju Yi,1,2,3,7 Devaveena Dey,1,2,3 Raman Nelakanti,1,2,3 Thomas P. Brouwer,1,2,3,4 David T. Paik,1,2,3 Idit Sagiv-Barfi,5 Arnold Han,6,11,12 Paul H.A. Quax,4 Jaap F. Hamming,4 Ronald Levy,5 Mark M. Davis,6,11,12 and Joseph C. Wu1,2,3,14 1Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA 2Stanford Cardiovascular Institute of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA 3Department of Radiology, Stanford University School of Medicine, Stanford, CA 94305, USA 4Department of Surgery, Leiden University Medical Center, Leiden 2333 ZA, the Netherlands 5Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA 6Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, CA 94305, USA 7Convergent Research Consortium for Immunologic Disease, Seoul St. Mary’s Hospital, Catholic University of Korea, Seoul 06591, Korea 8Max Delbru€ck Center for Molecular Medicine in the Helmholtz Association (MDC), Robert-Rossle Strasse 10, 13125 Berlin, Germany 9DZHK (German Centre for Cardiovascular Research), Partner Site, Berlin, Germany 10Berlin Institute of Health (BIH), Berlin, Germany 11Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA 12The Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94305, USA

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

Wrangle et al.
Lancet Oncology
Papers
April 2018
Authors and Affiliates
John M Wrangle1, Vamsidhar Velcheti2, Manish R Patel3, Elizabeth Garrett-Mayer1, Elizabeth G Hill1, James G Ravenel1, Jeffrey S Miller3, Mohammad Farhad4, Kate Anderton1, Kathryn Lindsey1, Michele Taffaro-Neskey1, Carol Sherman1, Samantha Suriano1, Marzena Swiderska-Syn1, Amy Sion1, Joni Harris1, Andie R Edwards1, Julie A Rytlewski5, Catherine M Sanders5, Erik C Yusko5, Mark D Robinson6, Carsten Krieg1, William L Redmond4, Jack O Egan7, Peter R Rhode7, Emily K Jeng7, Amy D Rock7, Hing C Wong7, Mark P Rubinstein8 1Department of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA. 2Cleveland Clinic, Cleveland, OH, USA. 3Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, USA. 4Earle A Chiles Research Institute, Portland, OR, USA. 5Adaptive Biotechnologies, Seattle, WA, USA. 6Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland. 7Altor BioScience, Miramar, FL, USA. 8Department of Medicine, Division of Hematology and Oncology, and Department of Surgery Medical University of South Carolina, Charleston, SC, USA.

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Forde et al.
New England Journal of Medicine
Papers
April 2018
Authors and Affiliates
P.M. Forde, J.E. Chaft, K.N. Smith, V. Anagnostou, T.R. Cottrell, M.D. Hellmann, M. Zahurak, S.C. Yang, D.R. Jones, S. Broderick, R.J. Battafarano, M.J. Velez, N. Rekhtman, Z. Olah, J. Naidoo, K.A. Marrone, F. Verde, H. Guo, J. Zhang, J.X. Caushi, H.Y. Chan, J.-W. Sidhom, R.B. Scharpf, J. White, E. Gabrielson, H. Wang, G.L. Rosner, V. Rusch, J.D. Wolchok, T. Merghoub, J.M. Taube, V.E. Velculescu, S.L. Topalian, J.R. Brahmer, and D.M. Pardoll From the Bloomberg-Kimmel Institute for Cancer Immunotherapy and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore (P.M.F., K.N.S., V.A., T.R.C., M.Z., S.C.Y., S.B., R.J.B., J.N., K.A.M., F.V., H.G., J.Z., J.X.C., H.Y.C., J.-W.S., R.B.S., J.W., E.G., H.W., G.L.R., J.M.T., V.E.V., S.L.T., J.R.B., D.M.P.); Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine (J.E.C., M.D.H., D.R.J., M.J.V., N.R., Z.O., V.R., J.D.W., T.M.) and the Ludwig Collaborative (J.D.W., T.M.) - all in New York; the Parker Institute for Cancer Immunotherapy, San Francisco (J.D.W., T.M.); and Swim Across America Laboratory, Charlotte, NC (J.D.W., T.M.).

Compositional characteristics of human peripheral TRBV pseudogene rearrangements

Shi et al.
Papers
Scientific Reports
April 2018
Authors and Affiliates
Bin Shi2,3, Long Ma1, Xiaoyan He1, Peipei Wu3, Peng Wang1, Xiaomei Wang1, Rui Ma1 & Xinsheng Yao1 1Department of Immunology, Research Center for Medicine & Biology, Innovation & Practice Base for Graduate Students Education, Zunyi Medical University, Zunyi, China. 2Department of Laboratory Medicine, The first Affiliated Hospital of Zunyi Medical University, Zunyi, China. 3School of Laboratory Medicine, Zunyi Medical University, Zunyi, China.

Cerebrospinal fluid immunoglobulin light chain ratios predict disease progression in multiple sclerosis

Rathbone et al.
Journal of Neurology
Neurosurgery
Papers
Psychiatry
April 2018
Authors and Affiliates
Emma Rathbone,1 Lindsay Durant,1 James Kinsella,1 Antony R Parker,2 Ghaniah Hassan-Smith,1 Michael R Douglas,3,4 S John Curnow5 1Centre for Translational Inflammation Research Institute of Inflammation and Ageing, College of Medical and Dental Sciences University of Birmingham, Birmingham, UK 2The Binding Site Group Ltd, Birmingham, UK 3Department of Neurology, Dudley Group NHS Foundation Trust, Russells Hall Hospital, Birmingham, UK 4School of Life and Health Sciences, Aston University, Birmingham, UK 5Centre for Translational Inflammation Research, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2WB, UK

Combination of ipilimumab and adoptive Cell Therapy with Tumor-infiltrating lymphocytes for Patients with Metastatic Melanoma

Mullinax et al.
Frontiers in Oncology
Papers
March 2018
Authors and Affiliates
John E. Mullinax1,2, MacLean Hall2, Sangeetha Prabhakaran3, Jeffrey Weber4, Nikhil Khushalani5, Zeynep Eroglu5, Andrew S. Brohl1,5, Joseph Markowitz2,5, Erica Royster5, Allison Richards5, Valerie Stark5, Jonathan S. Zager1,5, Linda Kelley2, Cheryl Cox2, Vernon K. Sondak5, James J. Mulé2,5, Shari Pilon-Thomas2,5 and Amod A. Sarnaik2,5 1Sarcoma Department, Moffitt Cancer Center, Tampa, FL, United States, 2Immunology Department, Moffitt Cancer Center, Tampa, FL, United States, 3Department of Surgery, University of New Mexico, Albuquerque, NM, United States, 4NYU Langone Medical Center, New York, NY, United States, 5Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, United States

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

Herrera et al.
Blood
Papers
March 2018
Authors and Affiliates
Alex F. Herrera,1 Alison J. Moskowitz,2 Nancy L. Bartlett,3 Julie M. Vose,4 Radhakrishnan Ramchandren,5 Tatyana A. Feldman,6 Ann S. LaCasce,7 Stephen M. Ansell,8 Craig H. Moskowitz,2 Keenan Fenton,9 Carol Anne Ogden,9 David Taft,9 Qu Zhang,9 Kazunobu Kato,10 Mary Campbell,9 and Ranjana H. Advani11 1City of Hope National Medical Center, Duarte, CA; 2Memorial Sloan Kettering Cancer Center, New York, NY; 3Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO; 4University of Nebraska Medical Center, Omaha, NE; 5Karmanos Cancer Institute, Detroit, MI; 6Hackensack University Medical Center, Hackensack, NJ; 7Dana-Farber Cancer Institute, Boston, MA; 8Mayo Clinic, Rochester, MN; 9Seattle Genetics, Inc, Bothell, WA; 10Bristol-Myers Squibb, Princeton, NJ; and 11Stanford University Medical Center, Palo Alto, CA

Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma

Usmani et al.
Experimental Hematology & Oncology
Papers
February 2018
Authors and Affiliates
Saad Z. Usmani1, Imran Khan2, Christopher Chiu3, David Foureau1, Lawrence J. Druhan1, Katherine Rigby1, Tineke Casneuf4, and A. Kate Sasser3 1Levine Cancer Institute/Carolinas Health Care System, 1021 Morehead Medical Drive, Charlotte, NC 28204 USA., 2Janssen Research & Development, LLC, Raritan, NJ USA., 3Janssen Research & Development, LLC, Spring House, PA USA., 4Janssen Research & Development, Beerse, Belgium.

RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis

Cortes et al.
Cancer Cell
Papers
February 2018
Authors and Affiliates
Jose R. Cortes,1 Alberto Ambesi-Impiombato,1 Lucile Couronné,2,3,4 S. Aidan Quinn,1 Christine S. Kim,1 Ana C. da Silva Almeida,1 Zachary West,1 Laura Belver,1 Marta Sanchez Martin,1 Laurianne Scourzic,5,6,7 Govind Bhagat,8 Olivier A. Bernard,5,6,7 Adolfo A. Ferrando,1,8,9 and Teresa Palomero1,8 1Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA, 2Department of Adult Hematology, Necker Hospital, Paris 75993, France, 3INSERM U 1163, CNRS ERL 8254, Institut Imagine, Paris 75015, France, 4Paris Descartes University, Paris 75006, France, 5Gustave Roussy, Villejuif 94805, France, 6INSERM U1170, Villejuif 94805, France, 7Universite Paris-Sud, Orsay 91400, France, 8Department of Pathology and Cell Biology, Columbia University Medical Center, 1130 St Nicholas Avenue, ICRC-401B, New York, NY 10032, USA, 9Department of Pediatrics, Columbia University Medical Center, New York, NY 10032, USA

Alloreactive T cell Receptor Diversity Against Structurally Similar or Dissimilar HLA-DP Antigens Assessed by Deep Sequencing

Arrieta-Bolaños et al.
Frontiers in Immunology
Papers
February 2018
Authors and Affiliates
Esteban Arrieta-Bolaños1, Pietro Crivello1, Maximilian Metzing1, Thuja Meurer1, Müberra Ahci1, Julie Rytlewski2, Marissa Vignali2, Erik Yusko2, Peter van Balen3, Peter A. Horn4, J. H. Frederik Falkenburg3, and Katharina Fleischhauer1,5 1Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany, 2Adaptive Biotechnologies, Seattle, WA, United States, 3Department of Hematology, Leiden University Medical Center, Leiden, Netherlands, 4Institute for Transfusion Medicine, University Hospital Essen, Essen, Germany, 5German Cancer Consortium (DKTK), Heidelberg, Germany Abstract Reference